Company Overview of BioNJ Inc.
BioNJ Inc. operates a network of members representing research-based life sciences companies and other related contributors. It stimulates and supports the discovery, development, and commercialization of therapies and cures by companies engaged in biopharmaceutical, biomedical, bio-agricultural, and bio-remedial endeavors. The company also provides purchasing consortium programs; and talent services, such as mentor networks, talent acquisitions, training and education, transition programs, HR networking, jobs databases and links, and specialty services for human resources and staffing requirements. In addition, it offers programs on project management, leadership, Six Sigma, root cause anal...
1255 Whitehorse-Mercerville Road
Building B – Suite 514
Trenton, NJ 08691
Founded in 1994
Key Executives for BioNJ Inc.
Chief Executive Officer, President and Trustee
Vice President of Operations
Vice President of Communications and Marketing
Compensation as of Fiscal Year 2016.
BioNJ Inc. Key Developments
BioNJ Inc. Presents at BioNJ's 4th Annual CEO Summit, Sep-23-2016 08:15 AM
Sep 20 16
BioNJ Inc. Presents at BioNJ's 4th Annual CEO Summit, Sep-23-2016 08:15 AM. Venue: Bridgewater Marriott, New Jersey, United States. Speakers: Debbie Hart, Chief Executive Officer, President and Trustee.
BioNJ Approves Appointment of Daniel J. O’Connor to Board of Directors
Feb 8 16
Advaxis Inc. announced that Daniel J. O’Connor, President and Chief Executive Officer, has been elected to the Board of Trustees of BioNJ. The election took place at the annual meeting of BioNJ. Mr. O’Connor has 20 years of executive, legal and regulatory experience in the biopharmaceutical industry, including senior leadership positions at ImClone Systems and PharmaNet. At ImClone, Mr. O’Connor served as senior vice president, general counsel and secretary, and he supported the clinical development, launch and commercialization of ERBITUX® (cetuximab), and helped resolve corporate issues, including extensive licensing negotiations, in advance of its sale to Eli Lilly in 2008.
BioNJ Welcomes Linda Brown as Vice President, Engagement
Dec 15 15
BioNJ announced that Linda Brown joined the organization as Vice President, Engagement. Linda brings more than 25 years in clinical research and drug development in the pharmaceutical and biotechnology industries in the U.S. and as an expatriate internationally. She has worked both in early stage and large company environments, including 13 years with Merck and Company in roles spanning manufacturing, clinical research and drug development, public and investor relations, fund raising, marketing and business development. Throughout her career, Linda has held leadership and liaison positions engaging teams and organizations to provide strategic direction to emerging companies and new business initiatives. Most recently Linda served as a global team leader at PAREXEL.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|